WHITEHOUSE, N.J.--(www.intertek.com), the leading provider of quality and safety services to a wide range of industries, is pleased to announce a successful general compliance audit by the US Food and Drug Administration. This means that the cGMP facility now has successfully completed 4 consecutive FDA audits over the past 10 years with no 483s.)--Intertek (
“This outcome only reinforces Intertek’s commitment to providing the most comprehensive and compliant development and testing services within our industry.”
The FDA investigators performed a thorough and wide-ranging audit, reviewing data from in areas such as method development and validation, risk assessment of data systems, stability testing and training of scientific personnel.
“Completing this extensive Good Manufacturing Practices (cGMP) audit in which again no Form-483 was issued attests to our continued focus on maintaining and improving our quality systems.” stated Mr. Neil Chapman, Vice President – Americas for Intertek Chemicals & Pharmaceuticals. “This outcome only reinforces Intertek’s commitment to providing the most comprehensive and compliant development and testing services within our industry.”
Intertek is the leading quality solutions provider to industries worldwide. From auditing and inspection, to testing, training, advisory, quality assurance and certification, Intertek adds value to customers’ products, processes and assets. With a network of more than 1,000 laboratories and offices and over 35,000 people in more than 100 countries, Intertek supports companies’ success in a global marketplace. Intertek helps its customers to meet end users’ expectations for safety, sustainability, performance, integrity and desirability in virtually any market worldwide. Intertek Group plc (LSE: ITRK) is listed on the London Stock Exchange and is a constituent of the FTSE 100 index. Visit: www.intertek.com